GMDA

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 9, 2023

Gamida Cell Ltd.

(Exact name of registrant as specified in its Charter)

(617) 892-9080

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐  

Item 7.01. Regulation FD Disclosure.

On January 9, 2023, Gamida Cell Ltd. (the “Company”) posted an updated corporate presentation on the Company’s website. To access the presentation, investors should visit the “Investors & Media” section of the Company’s website at www.gamida-cell.com.

The information furnished under this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 8.01 Other Events.

In the fourth quarter of 2022, the Israeli Ministry of Health and the United States Food and Drug Administration (the “FDA”) completed physical inspections of the Company's Kiryat Gat, Israel manufacturing facility. The Company will commercially manufacture omidubicel for sale in the United States at such facility if omidubicel is approved for marketing by the FDA.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

2

Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From May 2023 to Jun 2023

Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Jun 2022 to Jun 2023